BioSpace News Archive

ANI Pharmaceuticals, Inc. (“ANI”) (Nasdaq: ANIP) today announced that Arthur S. Przybyl will depart as President and Chief Executive Officer on May 10, 2020 . The Board of Directors has retained a nationally recognized executive search firm to lead the search for a new President and Chief Executive Officer. Mr. Przybyl said,

MyHealthTeams, creator of the largest and fastest-growing social networks for people facing chronic health conditions, today unveiled new research conducted among the more than 170,000 registered members of MyLupusTeam, the social network for people facing lupus.

SimX has announced immediate availability of two free multiplayer virtual reality training cases focused on the evaluation and management of COVID-19. Developed by ED docs working in hot zones in Washington and California, these cases allow doctors, nurses, and others to practice PPE, triage, evaluation, and inpatient treatment of COVID-19 patients.

Medtec China 2020 will be held from September 14–16 at SWEECC Halls 2&4 this year, “MDiT Forum and Regulation Summit 2020" is also going to return, continuing to focus on “regulations, quality and technology,” joining hands with medical device industry authorities and experts, to bring a unique industry education opportunity.

Onco360 ® , the nation’s largest independent Oncology Pharmacy, has been selected by AstraZeneca to be a specialty pharmacy partner for KOSELUGO™ (selumetinib), a novel oral kinase inhibitor indicated for the treatment of pediatric patients aged two years and above, with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas. “The approval of KOSELUGO represents a new treatment st

Epirium Bio Inc., a clinical-stage biopharmaceutical company focused on mitochondrial biogenesis and complementary therapeutic approaches as a means to addressing neuromuscular diseases and neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for its unique, orally available, synthetic flavanol EB 002 ((+)-epicatechin) for the treatment of Duchenne an

Allowed Claims Capture Different Dosage Regimens to be the Focus of Ongoing Research

XBiotech Inc. (NASDAQ: XBIT) announced today that a novel antibody it has discovered that neutralizes interleukin-1 alpha (IL-1⍺) has now been advanced as a product candidate for clinical and commercial development. XBiotech discovered the IgG1 monoclonal antibody from a healthy donor with natural immunity against IL-1⍺. Creating medicines from natural human immunity is the hallmark of XBiotech’s approach to developing a new generation of break

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor f

The Learning Corp, an award-winning digital therapeutics provider, today announced that it has received Breakthrough Device designation from the United States Food and Drug Administration (FDA) for its Speech Therapy (ST) App, which is designed to provide accessible cognitive, speech and language therapy to stroke patients.